Hospital Pharmacy Europe

AUGUST 31, 2023

The use of intravenous ferric carboxymaltose (FCM) in heart failure patients with iron deficiency reduces the risk of hospitalisation and cardiovascular death, according to research presented at the recent European Society for Cardiology (ESC) Congress 2023 in Amsterdam. b- 1.02, P = 0.076). p = 0.025). p = 0.025).

Hospitals 97

Hospitals 97

Pharmacy Times

JANUARY 5, 2024

Conclusions could not be made regarding whether lower risk was associated with improvement in heart failure or if the success of optimal medications led to better clinical outcomes.

120

120

Hospital Pharmacy Europe

MAY 22, 2023

NICE has recommended the extension of dapagliflozin as a treatment option for symptomatic chronic heart failure in patients with preserved or mildly reduced ejection fraction. This follows EU approval of dapagliflozin across all ejection fractions in heart failure in February 2023.

Hospitals 98

Hospitals 98

Pharmacy Times

OCTOBER 1, 2022

Empagliflozin has been found to lower the risk of death due to cardiovascular events and the number of first and recurrent heart failure hospitalizations.

Hospitals 122

Hospitals 122

The Checkup by Singlecare

MARCH 21, 2024

One of the most remarkable stories in medicine over the past few years has been the expanding use of a diabetes drug class as therapy for heart failure. The drug was developed for the treatment of Type 2 diabetes mellitus and then found to be remarkably beneficial for treating congestive heart failure, even for those without diabetes.

Insurance 98

Insurance Adverse Reactions FDA Dosage 98

Pharmacy Times

JUNE 5, 2023

Treatment with Injectafer significantly improved exercise capacity compared to placebo in a randomized clinical trial in adult patients with heart failure.

FDA 132

FDA 132

The Checkup by Singlecare

APRIL 19, 2024

Heart failure is a long-term condition that can affect one or both sides of the heart and occurs when the heart cannot pump enough blood. Heart failure causes fluid buildup as well as decreased blood flow to the organs. Farxiga is one of the treatment options for heart failure.

Insurance 52

Insurance Dosage Hospitals FDA 52

Pharmacy Times

JUNE 2, 2023

Management of heart failure focuses on avoiding reversible precipitants and optimizing guideline-directed therapy to lower mortality and hospitalizations.

Hospitals 65

Hospitals 65

European Pharmaceutical Review

MAY 19, 2023

Final draft guidance has been published for the first National Institute for Health and Care Excellence (NICE)-recommended treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. The study enrolled 6,263 randomised patients. This was reported as 16.4 percent in the dapagliflozin group and 19.5

Hospitals 104

Hospitals 104

STAT

OCTOBER 16, 2023

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed. billion, sells devices for heart failure patients as well as patient monitoring software.

FDA 137

FDA 137

pharmaphorum

AUGUST 8, 2022

A study of a mobile health app used to support patients hospitalised with heart failure has concluded that it provided a modest improvement in quality-of-life scores, as well as better clinical outcomes. It can be bewildering for heart failure patients to implement the advice of their doctors, says Pattern Health.

Hospitals 145

Hospitals 145

European Pharmaceutical Review

NOVEMBER 21, 2022

The first-in-human gene therapy trial for heart failure patients with preserved ejection fraction (HFpEF) has been approved by the US Food & Drug Administration (FDA). Heart failure with preserved ejection fraction. The syndrome accounts for half of all heart failure cases globally.

Labelling 131

Labelling FDA 131

Pharmacy Times

JANUARY 18, 2023

Study results shows that the use of a point-of-care tool and timely after care were essential to lowering the risk of hospitalization from cardiovascular disease within 30 days after acute HF.

Hospitals 65

Hospitals 65

STAT

JULY 17, 2023

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death. Continue to STAT+ to read the full story…

Hospitals 92

Hospitals 92

pharmaphorum

APRIL 25, 2022

An analysis of 10 clinical trials of digital health interventions targeted at patients recently hospitalised for acute heart failure has found they improve outcomes compared to standard care. Patients in the digital arms also lost fewer days due to hospitalisation for heart failure – 1.77 with usual care to 8.5%

Hospitals 139

Hospitals 139

European Pharmaceutical Review

AUGUST 8, 2023

Tom Keith-Roach, President of AstraZeneca UK announced: “We are pleased that the SMC has now accepted Forxiga (dapagliflozin) for use in patients with chronic heart failure with preserved or mildly reduced ejection fraction and Tezspire (tezepelumab) has been accepted for restricted use in severe asthma within NHS Scotland.”

90

90

Hospital Pharmacy Europe

OCTOBER 12, 2023

NICE has recommended empagliflozin as a treatment option for some patients with chronic heart failure. The drug (brand name Jardiance) can be considered as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults, final draft guidance states.

Dosage 52

Dosage Hospitals 52

Hospital Pharmacy Europe

AUGUST 31, 2023

The use of intravenous ferric carboxymaltose (FCM) in heart failure patients with iron deficiency reduces the risk of hospitalisation and cardiovascular death, according to research presented at the recent European Society for Cardiology (ESC) Congress 2023 in Amsterdam. b- 1.02, P = 0.076). p = 0.025). p = 0.025).

Hospitals 52

Hospitals 52

European Pharmaceutical Review

FEBRUARY 28, 2023

The largest cell therapy trial to date for chronic heart failure due to low ejection fraction (EF), has shown that mesenchymal precursor cells (MPCs) have potential for the first time to address inflammation. For the first time, we’ve discovered that stem cells can successfully treat the inflammation that causes heart failure.”

99

99

pharmaphorum

SEPTEMBER 6, 2021

UK researchers have used artificial intelligence (AI) to develop a way to identify patients with heart failure who would benefit from treatment with beta blockers, by interrogating data from nine landmark clinical trials. The post AI could be used to guide drug therapy for heart failure appeared first on.

145

145

pharmaphorum

MARCH 3, 2022

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with the condition. The post Stage set for Jardiance to become universal heart failure drug appeared first on.

Labelling 98

Labelling Hospitals 98

STAT

OCTOBER 9, 2023

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

FDA 123

FDA 123

pharmaphorum

NOVEMBER 16, 2021

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart failure. As its name suggests, VEGF is a protein that stimulates formation of new blood vessels and repair of damaged heart muscle.

Vaccines 129

Vaccines Hospitals 129

Fierce Healthcare

FEBRUARY 22, 2024

Through a partnership with Story Health, ChristianaCare has been able to improve care for Black patients living with heart failure and plans to expand the collaboration to other patients. At ChristianaCare, patients saw a significant improvement on several key metrics, including readmission rates.

68

68

Hospital Pharmacy Europe

MARCH 12, 2024

Patients with kidney failure are at ‘an unacceptably high risk’ of myocardial infarction and stroke, but simple treatment strategies could make a difference, a study funded by the British Heart Foundation has found. Between 1996 and 2016, amongst 16,050 patients with kidney failure (52±15 years; 41.5% in 1996 to 7.25

Hospitals 52

Hospitals 52

STAT

JANUARY 2, 2024

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: In December, Vertex Pharmaceuticals announced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain.

107

107

European Pharmaceutical Review

FEBRUARY 7, 2023

Forxiga (dapagliflozin) has been approved in the European Union for heart failure (HF) with reduced ejection fraction (HFrEF) across the full spectrum of left ventricular ejection fraction (LVEF). AstraZeneca’s Forxiga is the first and only heart failure therapy with proven mortality benefit across the full ejection fraction range.

89

89

Hospital Pharmacy Europe

JANUARY 19, 2023

Heart failure is growing public health concern with an estimated global prevalence exceeding 37.7 Moreover, some evidence points to a lower mortality in patients with congestive heart failure treated with torsemide compared to furosemide. million people.

Hospitals 95

Hospitals Labelling 95

Pharmafile

FEBRUARY 8, 2023

Published date: 08/02/2023 Summary: • Data from GLPi animal studies demonstrate safety of second-generation DSRii product (DSR 2.0) • Data from Phase 1 study of DSR 2.0 in Mexico (CHIHUAHUA) and INDiii filing to US FDA expected in Q1 2023 • Planning to start MOJAVE, a US Phase 1/2a randomized controlled multi-center study of DSR 2.0,

FDA 72

FDA 72

pharmaphorum

NOVEMBER 15, 2021

Johnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms in a clinical trial that relied entirely on remote monitoring of symptoms using a smartphone app.

Labelling 105

Labelling FDA 105

STAT

MAY 20, 2023

An early-stage drug for a heart disease called ATTR-CM showed potential to reverse disease progression, opening up a new way of attacking the condition as existing drugs have been designed to only slow or stall the disease. Continue to STAT+ to read the full story…

107

107

pharmaphorum

FEBRUARY 25, 2022

Eli Lilly and Boehringer Ingelheim’s blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food and Drug Administration (FDA) for a wider range of heart failure patients. . According to the FDA, heart disease impacts more than 650,000 people in the US each year.

FDA 100

FDA 100

Pharmaceutical Technology

DECEMBER 20, 2023

Rexlemestrocel-L is under clinical development by Mesoblast and currently in Phase III for Congestive Heart Failure (Heart Failure).

40

40

European Pharmaceutical Review

DECEMBER 12, 2022

The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF). Clinical trial data assessing dapagliflozin for chronic heart failure.

104

104

STAT

DECEMBER 6, 2023

In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Insurance 115

Insurance 115

Pharmaceutical Technology

DECEMBER 20, 2023

MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF).

52

52

Hospital Pharmacy Europe

FEBRUARY 2, 2023

Increasing the time between catheter ablation and a diagnosis of atrial fibrillation (AF) is associated with worse outcomes for patients both with or without co-existing heart failure, according to an analysis by US researchers. In a 2013 study, researchers found that delaying ablation worsened the success of the procedure.

Hospitals 97

Hospitals 97